1,086 material Form 8-K filings that 883 companies we cover made with the SEC in July 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Franklin Electric's board appointed Jennifer Wolfenbarger as Vice President, Chief Financial Officer and Chief Accounting Officer on July 7, 2025, succeeding interim CFO Russell Fleeger, who had served since March 28, 2025. The filing sets her pay package, including a $500,000 base salary and a target equity award of an estimated $1.1 million, which matters to shareholders as a change in the company's top financial role.
Appointed July 7, 2025, succeeding interim CFO Russell Fleeger, who served since March 28, 2025.
Annual base salary of $500,000 and target bonus of 75% of base salary, prorated for 2025, plus a $75,000 signing bonus.
Equity award with an estimated target total value of $1.1 million; 55% vests after one year and 45% after two years.
Previous CFO's departure was previously announced; her prior role was divisional CFO at Owens Corning.
Integer Holdings appointed Michael J. Coyle, former president and CEO of iRhythm Technologies, to its Board of Directors on July 10, 2025, increasing the Board from 10 to 11 seats. The filing describes no financial results or guidance, so the change is a governance update rather than a change in the company's financial outlook.
Michael J. Coyle joined the Board effective July 10, 2025, with his term running to the next annual stockholder meeting.
Coyle will serve on the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee.
He previously served as president and CEO of iRhythm Technologies and as executive vice president and group president of Medtronic's cardio and vascular group.
Director compensation follows the Company's Director Compensation Policy, as described in the April 7, 2025 Annual Proxy Statement.
GEO Group amended executive chairman George Zoley's employment agreement, extending his term to April 2, 2029 and raising his target bonus and target stock award from 100% to 150% of base salary. The Compensation Committee also raised CEO J. David Donahue's target bonus and target stock award from 100% to 150% of his base salary, citing the company's business opportunities and the executives' experience.
Zoley's term as Executive Chairman extended from June 30, 2026 to April 2, 2029
Zoley's target bonus and target stock award raised from 100% to 150% of base salary; amendment dated July 7, 2025
Committee approved Donahue's target bonus and target stock award increase from 100% to 150% of base salary on July 3, 2025
Sterling Infrastructure, Inc. appointed B. Andrew Rose and David Schulz to its Board of Directors effective July 10, 2025, and increased the Board's size. The filing says the Board is now eight directors, seven of them independent, and each new director receives a pro-rated restricted stock award valued at $111,698.
Rose and Schulz are appointed as directors effective July 10, 2025, and serve until the 2026 annual meeting of shareholders.
Rose joins the Compensation and Talent Development Committee and the Corporate Governance and Nominating Committee; Schulz joins the Compensation and Talent Development Committee and the Audit Committee.
The Board determined Schulz qualifies as an audit committee financial expert under SEC rules.
Each new director receives a pro-rated restricted stock award valued at $111,698.
Jazz Pharmaceuticals said its board appointed President and Chief Operating Officer Renee Gala as President and Chief Executive Officer, effective August 11, 2025, and she will join the board as a director on that date. Co-founder Bruce Cozadd will serve as CEO until August 11, 2025, then in a transition role through September 12, 2025, before retiring and remaining Chairperson of the Board.
Gala becomes CEO and a director effective August 11, 2025; the board increases from 12 to 13 members.
Gala's annual base salary rises to $1,200,000 from $900,000, and her target bonus to 110% of base salary from 80%.
A one-time promotion equity grant with an approximate grant date value of $6,500,000 is included, on top of her previous 2025 annual grant of approximately $6,000,000.
Cozadd remains in a transition role through September 12, 2025, then retires and continues as Chairperson.
IDEXX Laboratories added Joseph L. (Jay) Hooley, former Chair and CEO of State Street Corporation, as an independent director effective July 10, 2025. The board expanded from nine to ten directors, and Mr. Hooley joined the Audit Committee and the Governance and Corporate Responsibility Committee. The filing reports no financial results or guidance changes; the appointment is a board governance change.
Joseph L. (Jay) Hooley elected as an independent Class III Director effective July 10, 2025
Board size increased from nine to ten directors; Class III seats increased from three to four
Appointed to the Audit Committee and Governance and Corporate Responsibility Committee
Director stock grants to Mr. Hooley scheduled for September 1, 2025, prorated to the 2026 annual meeting
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.